Drugs / ceftazidime/avibactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07431307 | Jul 2026 → Mar 2028 expected | bacterial meningitis, bacterial pneumonia | BioVersys AG | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ceftazidime/avibactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431307 ↗ |
| Route | Intravenous | “ceftazidime/avibactam\*,# infused over 2 hours every 8 hours (q8h)” NCT07431307 ↗ |